Emerging targeted therapies in oral oncology: Focus on EGFR inhibition

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition

This comprehensive study explored the role of epidermal growth factor receptor (EGFR)-targeted therapies in oral cancer, focusing on emerging strategies, challenges, and future directions. The EGFR signalling pathway plays a critical role in the development and progression of oral cancer, making it...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vishnu Priya Veeraraghavan, Shikhar Daniel, Arun Kumar Dasari, Kaladhar Reddy Aileni, Chaitra patil, Santosh R. Patil
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Series:	Oral Oncology Reports
Subjects:	Epidermal growth factor receptor (EGFR) Oral cancer Targeted therapy Tyrosine kinase inhibitors (TKIs) Monoclonal antibodies (mAbs) Combination therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772906024004382
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
by: Huiyun Lv, et al.
Published: (2025-02-01)

Harnessing artificial intelligence for predictive modelling in oral oncology: Opportunities, challenges, and clinical Perspectives
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01)

Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach
by: Xingping Zhang, et al.
Published: (2025-01-01)

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
by: Piyada Sitthideatphaiboon, et al.
Published: (2025-01-01)

A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified  Lung Squamous Cell Carcinoma and Literature Review
by: Yalan LIU, et al.
Published: (2024-11-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Targeting Soluble Amyloid Oligomers in Alzheimer’s Disease: A Hypothetical Model Study Comparing Intrathecal Pseudodelivery of mAbs Against Intravenous Administration
by: Manuel Menendez-Gonzalez
Published: (2025-01-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors
by: Letha Chemmalil, et al.
Published: (2025-01-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Deciphering genomic complexity: Understanding intratumor heterogeneity, clonal evolution, and therapeutic vulnerabilities in oral squamous cell carcinoma
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-06-01)

Rare skin adverse reactions induced by osimertinib: a case report and literature review
by: Ye Zhang, et al.
Published: (2025-01-01)

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age
by: Mototsugu Oya, et al.
Published: (2025-01-01)

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study
by: Fazeel Zubair Ahmed, et al.
Published: (2025-01-01)

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
by: Li Gong, et al.
Published: (2024-12-01)

Drugs as a cause of perforating dermatoses – a literature review
by: Lidia Mądrzak, et al.
Published: (2024-11-01)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01)

Corrigendum: Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2025-02-01)

Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2024-10-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars—Advice to Developers and Regulatory Agencies
by: Sarfaraz K. Niazi
Published: (2025-01-01)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2025-02-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
by: Ji Eun Shin, et al.
Published: (2025-02-01)

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
by: Sara Cherradi, et al.
Published: (2025-01-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Impact of the crosstalk between the PTEN and PAFR as well as PAFR and EGFR pathways in cancer
by: Anita Thyagarajan, et al.
Published: (2025-01-01)

Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand
by: Prakit Anukoolwittaya, et al.
Published: (2024-09-01)

In-situ biophysical characterization of high-concentration protein formulations using wNMR
by: Jing Song, et al.
Published: (2024-12-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
by: Bita Jafary, et al.
Published: (2025-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report
by: Sijia Zhang, et al.
Published: (2023-03-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)